Business
-
Orexo has announced that it will evaluate the ability of its AmorphOX dry powder platform to create stable formulations of SVF’s LNP-encapsulated mRNA vaccines for nasal delivery. Orexo has its own pipeline of intranasal dry… Read more . . .
-
US-based startup LionBio, which describes itself as “The Nasal Peptide Company,” has published a video announcing the company’s launch with $6 million in seed funding and nose-to-brain delivery technology developed at Columbia University developed by… Read more . . .
-
Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… Read more . . .
-
Aptar Pharma announced that it has acquired Pulmotree, the developer of the Kolibri mesh nebulizer, which it refers to as a non-propellant liquid inhaler. The Kolibri nebulizer is a breath-activated, connected device that provides real-time… Read more . . .
-
According to Liquidia, the company has reached a settlement with United Therapeutics to end all litigation related to patent infringement by Liquidia’s Yutrepia treprostinil DPI. A United States District Court judge recently ruled that Yutrepia… Read more . . .
-
Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler… Read more . . .
-
A judge in the United States District Court for the District of Delaware has found infringement by Liquidia of two claims included in US Patent No. 11,826,327 (“Treatment for interstitial lung disease”), which was issued… Read more . . .
-
The Cystic Fibrosis Foundation has agreed to invest up to $7.3 million in Ride Therapeutics to support identification of potential delivery vehicles for inhaled genetic therapies for CF. According to the CFF, Ride plans to test millions… Read more . . .
-
Inhaled mRNA developer Ethris has signed an agreement with the European Investment Bank (EIB), and the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA) for a €30 million financing to support clinical development… Read more . . .
-
Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


